Key result
Vaccination procedures, particularly an interferon-gamma-expressing recombinant Coxsackievirus variant, are effective in preventing Coxsackievirus B3-induced myocarditis in murine models.
Vaccination strategies, including recombinant viral variants, show promise in preventing Coxsackievirus B3-induced myocarditis in preclinical murine models.
Supports preclinical vaccine strategies for viral myocarditis; leaves open translation from murine models to human trials.
Coxsackievirus B3--a member of the picornavirus family--is one of the major causes of virus-induced acute or chronic heart disease. Despite the fact that the molecular structure of this pathogen has been characterized very precisely during the last 10 years, until recently, there was no virus-specific preventive or therapeutic procedure against Coxsackievirus B3-induced human heart disease in clinical use. However, using different murine model systems it has been demonstrated that classic as well as newly developed vaccination procedures are quite successful in preventing Coxsackievirus B3 infections. In particular, the application of an interferon-gamma-expressing recombinant Coxsackievirus variant against Coxsackievirus B3-induced myocarditis has been effective.
No takes yet. Share an insight, caveat, or question.
Henke et al. (2003) conducted a review in Coxsackievirus B3-induced heart disease. Vaccination procedures (e.g., interferon-gamma-expressing recombinant Coxsackievirus variant) was evaluated on Prevention of Coxsackievirus B3 infections and myocarditis. Vaccination procedures, particularly an interferon-gamma-expressing recombinant Coxsackievirus variant, are effective in preventing Coxsackievirus B3-induced myocarditis in murine models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: